One of these studies (NCT02414269), which investigated MSLN-directed chimeric antigen receptor (CAR) T cell therapy, presented preliminary results where decreased serum SMRP levels (<50% compared to pretreatment) were associated with CAR T cell persistence and tumor regression. This evidence concerns the gene MSLN and neoplasm.